In partnership with
Letter from the editor
Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis
Atopic dermatitis and psoriasis: on a spectrum?
Advances in target-oriented therapy: psoriatic arthritis
Favourable safety profile of long-term use of ixekizumab
Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies
Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients
Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis
Certolizumab: Long-term safety and efficacy results for psoriasis-related nail disease
Granulomatous rosacea: exploratory histological markers
Live imaging of cutaneous immune responses
Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?
ABP501 biosimilar for adalimumab: What you need to know
Switching infliximab biosimilars safe in treating chronic plaque psoriasis
Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis
Treatment goals in psoriasis
Small molecules, apremilast, and TYK2
Top image: © AGLPhotoproductions
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.
BACK TO TOP